The RYBELSUS®

Telehealth Guide

Helpful tips to keep in mind before your call

Keep this **reference guide** and other RYBELSUS® materials from sales representatives handy as resources to refer to during your virtual visit

Before hanging up, go over **next steps**, such as scheduling a follow-up, what information patients should take with them to the pharmacy (such as their savings offer, if eligible), or picking up their RYBELSUS® script

Indications and Usage

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Limitations of Use

- RYBELSUS® is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans
- RYBELSUS® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis
- RYBELSUS® is not indicated for use in patients with type 1 diabetes

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined**
- **RYBELSUS® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of RYBELSUS® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS®**

novo nordisk®

Please see Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at RYBELSUSpro.com.

RYBELSUS® semaglutide tablets 7mg | 14mg

Getting patients started on RYBELSUS® virtually

3 important things to cover about dosing and administration with RYBELSUS®

1

Ensure your patient understands what dosage of RYBELSUS® they'll be starting on and for how long[1]

START ON

3 mg — **The beginning dose is 3 mg for the first 30 days.** This will give your body a chance to get used to the medicine.

AND STAY ON

7 mg — **When you finish all of the 3 mg pills, you'll start your 7 mg prescription.**

- The 3 mg dose is intended for treatment initiation and is not effective for glycemic control. The prescribed 7 mg maintenance dose helps lower blood sugar. If more blood sugar control is needed after at least 30 days on the 7 mg maintenance dose, the 14 mg maintenance dose may be prescribed

Remember to pick up your 7 mg prescription from your pharmacy when you pick up your 3 mg dose.

Important Safety Information

Contraindications

- RYBELSUS® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with RYBELSUS®

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
- **Pancreatitis:** Has been reported in clinical trials. Observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue RYBELSUS® and initiate appropriate management; if confirmed, do not restart RYBELSUS®

novo nordisk®

Please see Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at RYBELSUSpro.com.

RYBELSUS® semaglutide tablets 7mg | 14mg

Getting patients started on RYBELSUS® virtually

3 important things to cover about dosing and administration with RYBELSUS®

2

Next, go over these important administration steps[1]

Take on an **empty stomach** when you first wake up

Take with **a sip of plain water** (no more than 4 oz)

Take at **least 30 minutes** before the first food, beverage, or other oral medications of the day

- Waiting less than 30 minutes, or taking with food, beverages (other than plain water), or other oral medications will lessen the effect of RYBELSUS® by decreasing its absorption
- Waiting more than 30 minutes to eat may increase the absorption of RYBELSUS®

Important Safety Information

- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, including semaglutide. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of RYBELSUS® in patients reporting severe adverse gastrointestinal reactions
- **Hypersensitivity:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with RYBELSUS®. If hypersensitivity reactions occur, discontinue use of RYBELSUS®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist

Adverse Reactions

- The most common adverse reactions, reported in ≥5% of patients treated with RYBELSUS® are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation

novo nordisk®

Please see Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at RYBELSUSpro.com.

RYBELSUS® semaglutide tablets 7mg | 14mg

Getting patients started on RYBELSUS® virtually

3

Review the proper storage for RYBELSUS®[1]

Go over the following storage instructions with your patients—they must follow these so that RYBELSUS® works as planned[1]:

Store tablets in the closed RYBELSUS® bottle until ready to take one

Do not use a pill organizer or other container to store RYBELSUS® tablets

Swallow tablet whole. Do not cut, crush, or chew them

Important Note: The RYBELSUS® blue cap is equipped with a drying agent to help protect the tablets from moisture, which helps preserve RYBELSUS®. Tablets should be kept in the RYBELSUS® bottle with the blue cap on whenever the patient is not taking one.

Store at room temperature 68°F-77°F (20°C-25°C). Store in a dry place away from moisture.

Important Safety Information

Drug Interactions

- When initiating RYBELSUS®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
- RYBELSUS® delays gastric emptying and has the potential to impact the absorption of other oral medications. Closely follow RYBELSUS® administration instructions when coadministering with other oral medications and consider increased monitoring for medications with a narrow therapeutic index, such as levothyroxine

Use in Specific Populations

- **Pregnancy:** Available data with RYBELSUS® are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to RYBELSUS®. Use only if the potential benefit justifies the potential risk to the fetus

Provide your patients with video links to view on their own time



To learn more about starting RYBELSUS®,

let your patients know they can visit:

RYBELSUS.com 〉 Why RYBELSUS®? 〉 RYBELSUS® Videos

Important Safety Information

Warnings and Precautions

- **Diabetic Retinopathy Complications:** In a pooled analysis of glycemic control trials with RYBELSUS®, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with RYBELSUS® and 3.8% with comparator). In a 2-year trial with semaglutide injection involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with semaglutide injection (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
- **Hypoglycemia:** Patients receiving RYBELSUS® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia

novo nordisk®

Please see Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at RYBELSUSpro.com.

RYBELSUS® semaglutide tablets 7mg | 14mg

If your patients have commercial insurance, they could be eligible for the RYBELSUS® savings offer[a]

3 ways patients can enroll:

ELIGIBLE PATIENTS PAY AS LITTLE AS **$10** FOR A 30-DAY PRESCRIPTION[a]

Have them visit SaveOnR.com
to download a savings card and receive email support

OR

Have them text READY to 21848[b]
to get the offer and helpful tips on how to start and stay on RYBELSUS®

OR

Call 1-833-ASK-A-CDE
for assistance with the savings offer Monday-Friday, 9 AM-6 PM (ET)

[a]For commercially insured patients only. Eligibility and other restrictions apply.
[b]Message and data rates may apply. Check with your mobile service provider. See Terms and Conditions of Use at RYBELSUS.com.

Important Safety Information

Use in Specific Populations

- **Lactation:** There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of salcaprozate sodium (SNAC), an absorption enhancer in RYBELSUS®, from breastfeeding and because there are alternative formulations of semaglutide that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with RYBELSUS®
- Discontinue RYBELSUS® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide
- **Pediatric Use:** Safety and efficacy of RYBELSUS® have not been established in pediatric patients (younger than 18 years)

Please see Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at RYBELSUSpro.com.

Reference: 1. RYBELSUS® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; April 2021.

RYBELSUS® semaglutide tablets 7mg | 14mg